These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 34650913)

  • 1. Resistance to Hypomethylating Agents in Myelodysplastic Syndrome and Acute Myeloid Leukemia From Clinical Data and Molecular Mechanism.
    Zhao G; Wang Q; Li S; Wang X
    Front Oncol; 2021; 11():706030. PubMed ID: 34650913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different mechanisms of drug resistance to hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukemia.
    Šimoničová K; Janotka Ľ; Kavcová H; Sulová Z; Breier A; Messingerova L
    Drug Resist Updat; 2022 Mar; 61():100805. PubMed ID: 35227933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishment and characterization of hypomethylating agent-resistant cell lines, MOLM/AZA-1 and MOLM/DEC-5.
    Hur EH; Jung SH; Goo BK; Moon J; Choi Y; Choi DR; Chung YJ; Lee JH
    Oncotarget; 2017 Feb; 8(7):11748-11762. PubMed ID: 28052028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing DNA hypomethylating therapy in acute myeloid leukemia and myelodysplastic syndromes.
    Straube J; Lane SW; Vu T
    Bioessays; 2021 Oct; 43(10):e2100125. PubMed ID: 34463368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel therapeutic strategies using hypomethylating agents in the treatment of myelodysplastic syndrome.
    Ishikawa T
    Int J Clin Oncol; 2014 Feb; 19(1):10-5. PubMed ID: 24357411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience.
    Pepe S; Scalzulli E; Colafigli G; Di Prima A; Diverio D; Mancini M; Latagliata R; Martelli M; Foà R; Breccia M
    Ann Hematol; 2020 Oct; 99(10):2405-2416. PubMed ID: 32813071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Digging deep into "dirty" drugs - modulation of the methylation machinery.
    Pleyer L; Greil R
    Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies.
    Stomper J; Rotondo JC; Greve G; Lübbert M
    Leukemia; 2021 Jul; 35(7):1873-1889. PubMed ID: 33958699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of hypomethylating agents in hematologic malignancies: treatment preferences and results.
    Serin I; Dogu MH
    Int J Hematol Oncol; 2021 Dec; 10(4):IJH37. PubMed ID: 35295753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival.
    Cabezón M; Malinverni R; Bargay J; Xicoy B; Marcé S; Garrido A; Tormo M; Arenillas L; Coll R; Borras J; Jiménez MJ; Hoyos M; Valcárcel D; Escoda L; Vall-Llovera F; Garcia A; Font LL; Rámila E; Buschbeck M; Zamora L;
    Clin Epigenetics; 2021 Jan; 13(1):9. PubMed ID: 33446256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of patients with higher-risk myelodysplastic syndromes after failure of hypomethylating agents: What is on the horizon?
    Bewersdorf JP; Zeidan AM
    Best Pract Res Clin Haematol; 2021 Mar; 34(1):101245. PubMed ID: 33762100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Targeted Therapy and Immunotherapy for Myelodysplastic Syndrome.
    Lee P; Yim R; Yung Y; Chu HT; Yip PK; Gill H
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world use and outcomes of hypomethylating agent therapy in higher-risk myelodysplastic syndromes: why are we not achieving the promise of clinical trials?
    Zeidan AM; Salimi T; Epstein RS
    Future Oncol; 2021 Dec; 17(36):5163-5175. PubMed ID: 34636250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update.
    Joeckel TE; Lübbert M
    Semin Hematol; 2012 Oct; 49(4):330-41. PubMed ID: 23079063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials.
    Yun S; Vincelette ND; Abraham I; Robertson KD; Fernandez-Zapico ME; Patnaik MM
    Clin Epigenetics; 2016; 8():68. PubMed ID: 27307795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ascertaining QUAZARs: slow-motion and light-speed development of oral azacitidine and decitabine.
    Feld J; Tremblay D; Navada SC; Silverman LR
    Leuk Lymphoma; 2023 Mar; 64(3):525-539. PubMed ID: 36370098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for Selective Benefit of Sequential Treatment With Hypomethylating Agents in Patients With Myelodysplastic Syndrome.
    Apuri S; Al Ali N; Padron E; Lancet JE; List AF; Komrokji RS
    Clin Lymphoma Myeloma Leuk; 2017 Apr; 17(4):211-214. PubMed ID: 28185797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypomethylating agents in the treatment of acute myeloid leukemia: A guide to optimal use.
    Santini V; Ossenkoppele GJ
    Crit Rev Oncol Hematol; 2019 Aug; 140():1-7. PubMed ID: 31153036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia.
    Saliba AN; John AJ; Kaufmann SH
    Cancer Drug Resist; 2021; 4(1):125-142. PubMed ID: 33796823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical update on hypomethylating agents.
    Duchmann M; Itzykson R
    Int J Hematol; 2019 Aug; 110(2):161-169. PubMed ID: 31020568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.